These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23425273)

  • 21. Development and calibration of a standard for the protein content of granulocyte colony-stimulating factor products.
    Gao K; Rao C; Tao L; Han C; Shi X; Wang L; Fan W; Yu L; Wang J
    Biologicals; 2012 Mar; 40(2):151-7. PubMed ID: 22296785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical platform for glycomic characterization of recombinant erythropoietin biotherapeutics and biosimilars by MS.
    Oh MJ; Hua S; Kim BJ; Jeong HN; Jeong SH; Grimm R; Yoo JS; An HJ
    Bioanalysis; 2013 Mar; 5(5):545-59. PubMed ID: 23425271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing analytical comparability for "biosimilars": filgrastim as a case study.
    Rathore AS; Bhambure R
    Anal Bioanal Chem; 2014 Oct; 406(26):6569-76. PubMed ID: 24866713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars: are they bioequivalent?
    Gomollón F
    Dig Dis; 2014; 32 Suppl 1():82-7. PubMed ID: 25531357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conference Report: Bioanalysis-related topics presented at the International Conference and Exhibition on Biowaivers and Biosimilars.
    Colletti KS
    Bioanalysis; 2013 Mar; 5(5):529-31. PubMed ID: 23425268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Key considerations in the preclinical development of biosimilars.
    Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
    Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.
    Chamberlain P
    Bioanalysis; 2013 Mar; 5(5):561-74. PubMed ID: 23425272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: State of Clinical and Regulatory Science.
    Klein AV; Wang J; Feagan BG; Omoto M
    J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.